CING News and Press, Cingulate Inc.

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now cent...

A look at the top 10 most actives in the United States Li Bang International Corporation Inc. (LBGJ) fell 2.3% to $0.03 on volume of 1,272,748,259 shares YY Group Holding Limited (YYGH) rose 17.1% to $0.0445 on volume of 686,036,167 shares VolitionRX Limited (VNRX) rose 5.3% to $0.2 on volu...

2026-03-18 16:16:48 ET More on Cingulate Seeking Alpha’s Quant Rating on Cingulate Historical earnings data for Cingulate Financial information for Cingulate Read the full article on Seeking Alpha For further details see: Cingulate reports ...

KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for t...

2026-03-16 13:26:25 ET Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm’s “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively...

A look at the top 10 most actives in the United States HCW Biologics Inc. (HCWB) rose 56.2% to $0.8061 on volume of 83,963,254 shares Tianci International Inc. (CIIT) rose 20.7% to $0.3621 on volume of 50,916,123 shares CytomX Therapeutics Inc. (CTMX) rose 46.9% to $6.8761 on volume of 45,1...

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led ...

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise. Recently the ...

Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Tim...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...